Skip to main content
Top
Published in: Pathology & Oncology Research 2/2017

01-04-2017 | Original Article

Relationships between Common and Novel Interleukin-6 Gene Polymorphisms and Risk of Cervical Cancer: a Case-Control Study

Authors: Sabrina Zidi, Mouna Stayoussef, Bano L. Alsaleh, Ezzedine Gazouani, Amel Mezlini, Bashayer H. Ebrahim, Besma Yacoubi-Loueslati, Wassim Y. Almawi

Published in: Pathology & Oncology Research | Issue 2/2017

Login to get access

Abstract

We investigated the association between six common and novel interleukin-6 (IL-6) polymorphisms with the risk of cervical cancer (CC) among Tunisians. Study subjects comprised 112 CC cases and 164 control women. Genotyping of IL-6 rs2069845, rs2069840, rs1474348, rs1800795, rs1800797, rs2069827 variants was done by real-time PCR, with defined clusters. The allelic and genotypic distributions of the tested IL-6 SNPs were comparable between CC patients and control women. Stratification according to FIGO staging revealed that rs1800795 homozygous major allele genotype (P = 0.033; OR =0.49(0.25–0.95)) and major allele (P = 0.037; OR = 0.57 (0.33–0.97)) were protective of CC. Moreover, carriage of rs1474348 major allele was also protective of CC (P = 0.014; OR = 0.53(0.32–0.88)), while higher rs1474348 minor allele frequency was seen in CC patients with early FIGO stage (P = 0.044; OR = 0.39 (0.15–1.00)), thus implicating rs1474348 in CC evolution and progression of angiogenesis. Haploview analysis demonstrated high linkage disequilibrium (LD) between rs2069845, rs2069840, rs1474348 and rs1800795, and 6-locus haplotype analysis identified GACCCA haplotype to be positively associated with increased CC, while GAGGGG haplotype was negatively associated with CC, thus suggesting a protective role for this haplotype in CC. Furthermore, there was a significant association between the incidence of CC and the use hormonal contraception (P = 0.047; OR = 1.97 (0.94–4.13)) and smoking (P < 0.001; OR = 7.12 (2.97–17.04)). The IL-6 variants rs1800795 and rs1474348, and haplotypes GACCCA and GAGGGG, along with use of hormonal contraceptives and smoking, are major risk factors of CC susceptibility and evolution among Tunisian women.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer Journal for Clinicians 61:69–90 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer Journal for Clinicians 61:69–90
4.
go back to reference Villa LL (2006) Biology of genital human papillomaviruses. International Journal of Gynecology and Obstetrics 94:3–7CrossRef Villa LL (2006) Biology of genital human papillomaviruses. International Journal of Gynecology and Obstetrics 94:3–7CrossRef
5.
go back to reference Rajeevan MS, Swan DC, Nisenbaum R, Lee DR, Vernon SD, Ruffin MT et al (2005) Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 115:114–120CrossRefPubMed Rajeevan MS, Swan DC, Nisenbaum R, Lee DR, Vernon SD, Ruffin MT et al (2005) Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 115:114–120CrossRefPubMed
6.
go back to reference Ribeiro KCB (2008) Cancer do colo do Utero: Epidemiologia do cancer do colo do utero – fatores demograficos e fatores de Risco. Tecmedd 18–23 Ribeiro KCB (2008) Cancer do colo do Utero: Epidemiologia do cancer do colo do utero – fatores demograficos e fatores de Risco. Tecmedd 18–23
7.
go back to reference Barton BE, Jackson JV (1993) Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 61:1496PubMedPubMedCentral Barton BE, Jackson JV (1993) Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 61:1496PubMedPubMedCentral
8.
go back to reference Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15–19CrossRefPubMed Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15–19CrossRefPubMed
9.
go back to reference Tartour E, Gey A, Sastre-Garau X, Pannetier C, Mosseri V, Kourilsky P et al (1994) Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 54:6243–6248PubMed Tartour E, Gey A, Sastre-Garau X, Pannetier C, Mosseri V, Kourilsky P et al (1994) Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 54:6243–6248PubMed
10.
go back to reference Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M, Musiani P (1997) Interleukin 1 alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 75:855–859CrossRefPubMedPubMedCentral Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M, Musiani P (1997) Interleukin 1 alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 75:855–859CrossRefPubMedPubMedCentral
11.
go back to reference Abdelwahab SI, Abdul AB, Zain ZN, Hadi AH (2012) Zerumbone inhibits interleukin-6 and induces apoptosis and cell cycle arrest in ovarian and cervical cancer cells. Int Immunopharmacol 12:594–602CrossRefPubMed Abdelwahab SI, Abdul AB, Zain ZN, Hadi AH (2012) Zerumbone inhibits interleukin-6 and induces apoptosis and cell cycle arrest in ovarian and cervical cancer cells. Int Immunopharmacol 12:594–602CrossRefPubMed
12.
go back to reference Zidi S, Stayoussef M, Gazouani E, Mezlini A, Yacoubi-Loueslati B, Almawi WY (2015) Relationship of common vascular endothelial growth factor polymorphisms and haplotypes with the risk of cervical cancer in Tunisians. Cytokine 74(1):108–112CrossRefPubMed Zidi S, Stayoussef M, Gazouani E, Mezlini A, Yacoubi-Loueslati B, Almawi WY (2015) Relationship of common vascular endothelial growth factor polymorphisms and haplotypes with the risk of cervical cancer in Tunisians. Cytokine 74(1):108–112CrossRefPubMed
13.
go back to reference Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741CrossRefPubMed Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741CrossRefPubMed
14.
go back to reference Wei L-H, Kuo M-L, Chen C-A, Cheng W-F, Cheng S-P, Hsieh F-J et al (2001) Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 82:49–56CrossRefPubMed Wei L-H, Kuo M-L, Chen C-A, Cheng W-F, Cheng S-P, Hsieh F-J et al (2001) Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 82:49–56CrossRefPubMed
15.
go back to reference Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N et al (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer 125:1851–1858CrossRefPubMed Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N et al (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer 125:1851–1858CrossRefPubMed
16.
go back to reference Gangwar R, Mittal B, Mittal RD (2009) Association of interleukin-6 -174G/C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24:11–16CrossRefPubMed Gangwar R, Mittal B, Mittal RD (2009) Association of interleukin-6 -174G/C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24:11–16CrossRefPubMed
17.
go back to reference Nogueira de Souza NC, Brenna SM, Campos F, Syrjanen KJ, Baracat EC, Silva ID (2006) Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 16:1278–1282CrossRefPubMed Nogueira de Souza NC, Brenna SM, Campos F, Syrjanen KJ, Baracat EC, Silva ID (2006) Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 16:1278–1282CrossRefPubMed
18.
go back to reference Shi T-Y, Zhu M-L, He J, Wang M-Y, Li Q-X, Zhou X-Y et al (2013) Polymorphisms of the interleukin 6 gene contribute to cervical cancer susceptibility in eastern Chinese women. Hum Genet 132:301–312CrossRefPubMed Shi T-Y, Zhu M-L, He J, Wang M-Y, Li Q-X, Zhou X-Y et al (2013) Polymorphisms of the interleukin 6 gene contribute to cervical cancer susceptibility in eastern Chinese women. Hum Genet 132:301–312CrossRefPubMed
19.
go back to reference Srivani R, Nagarajan B (2003) A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 13:331–339CrossRefPubMed Srivani R, Nagarajan B (2003) A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 13:331–339CrossRefPubMed
20.
go back to reference Porto CRC, de Oliveira Kleine JPF, Longatto AF, da Silva IDCG (2014) Polymorphism of interleukin-6 is not associated with the presence or absence of high HPV E6/E7. Anticancer Res 34:3501–3504PubMed Porto CRC, de Oliveira Kleine JPF, Longatto AF, da Silva IDCG (2014) Polymorphism of interleukin-6 is not associated with the presence or absence of high HPV E6/E7. Anticancer Res 34:3501–3504PubMed
21.
go back to reference Grimm C, Watrowski R, Baumühlner K, Natter C, Tong D, Wolf A et al (2011) Genetic variations of interleukin-1 and −6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol 121:537–541CrossRefPubMed Grimm C, Watrowski R, Baumühlner K, Natter C, Tong D, Wolf A et al (2011) Genetic variations of interleukin-1 and −6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol 121:537–541CrossRefPubMed
22.
go back to reference Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT e al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression—clinicopathological correlation. Gynecol Oncol 2007; 105: 157–165. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT e al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression—clinicopathological correlation. Gynecol Oncol 2007; 105: 157–165.
23.
go back to reference Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Investig 102(7):1369CrossRefPubMedPubMedCentral Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Investig 102(7):1369CrossRefPubMedPubMedCentral
24.
go back to reference Xu B, Niu X-B, Wang Z-D, Cheng W, Tong N, Mi Y-Y et al (2011) IL-6− 174G > C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 38(4):2589–2596CrossRefPubMed Xu B, Niu X-B, Wang Z-D, Cheng W, Tong N, Mi Y-Y et al (2011) IL-6− 174G > C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 38(4):2589–2596CrossRefPubMed
25.
go back to reference Zhang H, Xu Y, Li L, Liu R, Ma B (2012) The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int 88:447–453CrossRefPubMed Zhang H, Xu Y, Li L, Liu R, Ma B (2012) The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int 88:447–453CrossRefPubMed
26.
go back to reference Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008) Association of interleukin-6 (−174G > C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clincal Immunology 128:199–204CrossRef Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008) Association of interleukin-6 (−174G > C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clincal Immunology 128:199–204CrossRef
27.
go back to reference Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB et al (2008) Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity 16:339–347CrossRefPubMedPubMedCentral Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB et al (2008) Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity 16:339–347CrossRefPubMedPubMedCentral
28.
go back to reference Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S et al (2006) Strong association of interleukin-6 -174 G > C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21:246–250CrossRefPubMed Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S et al (2006) Strong association of interleukin-6 -174 G > C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21:246–250CrossRefPubMed
29.
go back to reference Grimm C, Six L, Tomovski C, Baumühlner K, Natter C, Tong D et al (2005) A common interleukin-6 promoter polymorphism in patients with vulvar cancer. J Soc Gynecol Investig 12:617–620CrossRefPubMed Grimm C, Six L, Tomovski C, Baumühlner K, Natter C, Tong D et al (2005) A common interleukin-6 promoter polymorphism in patients with vulvar cancer. J Soc Gynecol Investig 12:617–620CrossRefPubMed
30.
go back to reference Beral PV, de González AB, Colin D, Franceschi S, Goodhill A, Green J, Peto J et al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599):1609–1621 Beral PV, de González AB, Colin D, Franceschi S, Goodhill A, Green J, Peto J et al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599):1609–1621
31.
go back to reference Hea Young O (2016) Mi Kyung Kim, Sang-Soo Seo, Jae-Kwan Lee. Association of combined tobacco smoking and oral contraceptive use with cervical intraepithelial neoplasia 2 or 3 in Korean women. Journal of Epidemiology 26(1):22–29CrossRef Hea Young O (2016) Mi Kyung Kim, Sang-Soo Seo, Jae-Kwan Lee. Association of combined tobacco smoking and oral contraceptive use with cervical intraepithelial neoplasia 2 or 3 in Korean women. Journal of Epidemiology 26(1):22–29CrossRef
32.
go back to reference Nicol AF, Fernandes ATG, Grinsztejn B, Russomano F, Silva JRL, Tristão A et al (2005) Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection. Diagn Mol Pathol 14(1):39–47CrossRefPubMed Nicol AF, Fernandes ATG, Grinsztejn B, Russomano F, Silva JRL, Tristão A et al (2005) Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection. Diagn Mol Pathol 14(1):39–47CrossRefPubMed
Metadata
Title
Relationships between Common and Novel Interleukin-6 Gene Polymorphisms and Risk of Cervical Cancer: a Case-Control Study
Authors
Sabrina Zidi
Mouna Stayoussef
Bano L. Alsaleh
Ezzedine Gazouani
Amel Mezlini
Bashayer H. Ebrahim
Besma Yacoubi-Loueslati
Wassim Y. Almawi
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0127-9

Other articles of this Issue 2/2017

Pathology & Oncology Research 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine